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Abstract
Background—We previously developed two etomidate analogs that retain etomidate’s favorable
hemodynamic properties, but whose adrenocortical effects are reduced in duration or magnitude.
Methoxycarbonyl-etomidate (MOC-etomidate) is rapidly metabolized and ultra-short acting
whereas (R)-ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (carboetomidate) does not potently
inhibit 11β-hydroxylase. We hypothesized that MOC-etomidate’s labile ester could be
incorporated into carboetomidate to produce a new agent that possesses favorable properties
individually found in each agent. We describe the synthesis and pharmacology of
methoxycarbonyl-(R)-ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (MOC-carboetomidate), a
“soft” analog of carboetomidate.
Methods—MOC-carboetomidate’s octanol:water partition coefficient was determined
chromatographically and compared with those of etomidate, carboetomidate, and MOC-etomidate.
MOC-carboetomidate’s EC50 and ED50 for loss of righting reflexes (LORR) were measured in
tadpoles and rats, respectively. Its effect on gamma-aminobutyric acid A (GABAA) receptor
function was assessed using two-microelectrode voltage clamp electrophysiological techniques
and its metabolic stability was determined in pooled rat blood using high performance liquid
chromatography. Its duration of action and effects on arterial blood pressure and adrenocortical
function were assessed in rats.
Results—MOC-carboetomidate’s octanol:water partition coefficient was 3300 ± 280, whereas
those for etomidate, carboetomidate, and MOC-etomidate were 800 ± 180, 15000 ± 3700, and 190
± 25, respectively. MOC-carboetomidate’s EC50 for LORR in tadpoles was 9 ± 1 µM and its EC50
for LORR in rats was 13 ± 5 mg/kg. At 13 µM, MOC-carboetomidate enhanced GABAA receptor
currents by 400 ± 100%. Its metabolic half-life in pooled rat blood was 1.3 minutes. The slope of a
plot of the duration of LORR in rats versus the logarithm of the hypnotic dose was significantly
shallower for MOC-carboetomidate than for carboetomidate (4 ± 1 vs. 15 ± 3, respectively; p = 0.
0004123). At hypnotic doses, the effects of MOC-carboetomidate on arterial blood pressure and
adrenocortical function were not significantly different from those of vehicle alone.
Conclusions—MOC-carboetomidate is a GABAA receptor modulator with potent hypnotic
activity that is more rapidly metabolized and cleared from the brain than carboetomidate,
maintains hemodynamic stability similar to carboetomidate, and does not suppress adrenocortical
function.
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Etomidate is an imidazole-based IV sedative-hypnotic that is commonly used to induce
general anesthesia in elderly, critically ill, and hemodynamically unstable patients. 1–6
Unfortunately, etomidate binds with high affinity to 11b-hydroxylase, suppressing the
adrenocortical synthesis of steroids (i.e., cortisol, corticosterone, and aldosterone) that are
important regulators of immune function, glucose homeostasis, and water and electrolyte
balance. 7–9 Such suppression precludes etomidate administration as a prolonged continuous
infusion and has raised concerns regarding the administration of even a single bolus dose for
anesthetic induction. 10–14
We previously developed two etomidate analogs that retain etomidate’s favorable
hemodynamic properties, but whose effects on adrenocortical function are significantly
reduced in duration or magnitude (Figure 1). Methoxycarbonyl-etomidate (MOC-etomidate)
is a soft analog of etomidate that, similar to remifentanil and esmolol, contains a
metabolically labile ester group that is rapidly hydrolyzed by esterases. 15 In rats, MOC-
etomidate induces hypnosis of extremely short duration and does not produce prolonged
suppression of adrenocortical function because it is rapidly metabolized. 15 (R)-ethyl 1-(1-
phenylethyl)-1H-pyrrole-2-carboxylate (carboetomidate) is a pyrrole analog of etomidate
that was designed not to bind with high affinity to 11β-hydroxylase. 16 It is three orders of
magnitude less potent an inhibitor of in vitro cortisol synthesis and does not suppress steroid
synthesis in rats. 16
Respectively, MOC-etomidate and carboetomidate represent pharmacokinetic and
pharmacodynamic solutions to the problem of etomidate-induced adrenocortical
suppression. They were produced by modifying distinct regions of the etomidate molecular
scaffold in different ways. We hypothesized that these two modifications could be combined
to produce a single hypnotic drug that would possess advantageous properties found
individually in each agent. We describe the synthesis and pharmacology of
methoxycarbonyl-(R)-ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (MOC-
carboetomidate), a soft analog of carboetomidate.
Methods
Animals
All animal studies were conducted with the approval of the Subcommittee on Research
Animal Care at the Massachusetts General Hospital, Boston, Massachusetts. Xenopus laevis
tadpoles (early pre-limb stage) and adult female Xenopus laevis frogs were purchased from
Xenopus One (Ann Arbor, MI) and housed in our laboratory (tadpoles) or in the
Massachusetts General Hospital Center for Comparative Medicine animal care facility
(frogs). Adult male Sprague-Dawley rats (300–420g) were purchased from Charles River
Laboratories (Wilmington, MA) and housed in the Massachusetts General Hospital Center
for Comparative Medicine animal care facility. All drugs were administered via a femoral
venous catheter and all blood was drawn from a femoral venous or femoral arterial catheter.
Arterial blood pressure was measured using a femoral arterial catheter. All femoral venous
and arterial catheters were pre-implanted by the vendor.
Synthesis of Carboetomidate and MOC-carboetomidate
Carboetomidate was synthesized as previously described. 16 MOC-carboetomidate was
synthesized from carboetomidate starting material (Figure 2). A solution of carboetomidate
(5.85 g, 24 mmol) in MeOH (40 mL) was added to NaOH (6N, 12 ml). The resulting
mixture was heated to 50° C for 24h and then concentrated. The residue was acidified with
5N HCl and purified by silica gel column chromatography with dichloromethane/methanol
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to give the acid (4.4g, yield 86%). MS [M+1] = 216, 1HNMR (CDCl3): δ 7.23–7.34 (m,
3H), 7.15–7.18 (m, 3H), 7.05 (t, 1H, J = 2 Hz), 6.61 (q, 1H, J = 7.2Hz), 6.24 (dd, 1H, J = 4
Hz, J = 2.6Hz), 1.84 (d, 3H, J = 7.2 Hz).
To a mixture of the acid (4.4g, 20.5 mmol) and methyl-3-hydroxypropanoate (2.34g, 22.6
mmol) in anhydrous dichloromethane (100 ml), dicyclohexylcarbodiimide (4.66g, 22.6
mmol) and p-dimethylaminopyridine (2.76 g, 25.1 mmol) was added. The solution was
stirred at room temperature for 60 h. The precipitate was removed by filtration, and the clear
solution was applied to a silica gel column with dichloromethane/ether as eluents to give the
product with purity ~89%. The crude product was further purified by pre-high performance
liquid chromatography. The purified product was treated with HCl in dioxane to obtain
MOC-carboetomidate hydrochloride as a yellow oil (3.12g, 45% yield, purity>97%). MS [M
+1] = 302, 1HNMR (CDCl3): δ 7.24–7.30 (m, 3H), 7.15–7.17 (m, 2H), 7.02–7.03 (m, 1H),
7.01 (t, 1H, J = 2 Hz), 6.57 (q, 1H, J = 7.2Hz), 6.24 (dd, 1H, J = 4 Hz, J = 2.6Hz), 4.43–4.50
(m, 2H), 3.72 (s, 3H), 2.73 (t, 2H, J = 6.4Hz), 1.82 (d, 3H, J = 7.2 Hz).
Octanol:Water Partition Coefficients
One mg of MOC-carboetomidate, MOC-etomidate, carboetomidate, or etomidate was added
to 10 ml of water buffered with 10 mM Tris (pH 7.4) and 0.5 ml or 1 ml of octanol. The
mixture was stirred overnight and then centrifuged to more fully separate the organic and
aqueous phases. The relative concentrations of sedative-hypnotic in each phase (i.e., the
partition coefficient) was determined by high performance liquid chromatography using a
Varian Prostar system with a 4.6 × 250 mm Proto 300 C18 column (NEST Group,
Southborough, MA) with the UV detector set at 240nm. The mobile phase consisted of
water and acetonitrile with 0.05% trifluoroacetic acid (Thermo Scientific, Rockford, IL). A
linear gradient of 20% to 90% acetonitrile in water over 30 minutes was used with a flow
rate of 1 ml/min.
Loss of Righting Reflex (LORR) in Tadpoles
Groups of 5 Xenopus laevis tadpoles were placed in room temperature water buffered with
2.5 mM Tris HCl (pH=7.4) containing a concentration of MOC-carboetomidate that ranged
from 1 to 40 µM. Every 5 minutes, tadpoles were tipped with a flame-polished pipette until
the response stabilized. A tadpole was determined to have LORR if it failed to right itself
within 5 seconds after being turned supine. At the end of each study, tadpoles were returned
to fresh water to ensure reversibility. Tadpoles that did not regain their righting reflexes in
fresh water were excluded from the analysis. MOC-carboetomidate’s EC50 for LORR was
then determined from the concentration dependence of LORR using the quantal method of
Waud. 17
GABAA Receptor Electrophysiology
Adult female Xenopus laevis frogs were anesthetized with 0.2% tricaine (ethyl-m-
aminobenzoate) and hypothermia. Ovary lobes were then excised through a small
laparotomy incision and placed in OR-2 solution (82 mm NaCl, 2 mM KCl, 2 mM MgCl2, 5
mM HEPES, pH=7.5) containing collagenase 1A (1 mg/ml) for 3 hours to separate oocytes
from connective tissue.
Stage 4 and 5 oocytes were injected with messenger RNA encoding the α1, β2 (or
β2M286W), and γ2l subunits of the human gamma-aminobutyric acid A (GABAA) receptor
(−40 ng of messenger RNA total at a subunit ratio of 1:1:2). This messenger RNA was
transcribed from complementary DNA encoding for GABAA receptor α1, β2 (or
β2M286W), and γ2l subunits using the mMESSAGE mMACHINE High Yield Capped
RNA Transcription Kit (Ambion, Austin, TX). Injected oocytes were incubated in ND-96
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buffer solution (96 mM NaCl, 2 mM KCl, 1 mMCaCl2, 0.8 mM MgCl2, 10 mm HEPES,
pH=7.5) containing 50 U/ml of penicillin and 50 µg/ml of streptomycin at 17°C for at least
18 hours before electrophysiologic experiments.
All electrophysiologic recordings were performed using the whole cell two-electrode
voltage-clamp technique. Oocytes were placed in a 0.04-ml recording chamber and impaled
with capillary glass electrodes filled with 3 M KCl and possessing open tip resistances less
than 5 MΩ. Oocytes were then voltage clamped at −50 mV using a GeneClamp 500B
amplifier (Axon Instruments, Union City, CA) and perfused with ND-96 buffer at a rate of
4–6 ml/min. Buffer perfusion was controlled using a six-channel valve controller (Warner
Instruments, Hamden, CT) interfaced with a Digidata 1322A data acquisition system (Axon
Instruments) and driven by a Dell personal computer (Round Rock, TX). Current responses
were recorded using Clampex 9.2 software (Axon Instruments) and processed using a Bessel
(8-pole) low-pass filter with a cutoff at 50 Hz using Clampfit 9.2 software (Axon
Instruments).
For each oocyte, the concentration of GABA that produced 5–10% of the maximal current
response (EC5–10 GABA) was determined by measuring the peak current responses evoked
by a range of GABA concentrations (in ND-96 buffer) and comparing them with the
maximal peak current response evoked by 1 mM GABA. The effect of MOC-
carboetomidate on EC5–10 GABA-evoked currents was then assessed by perfusing the
oocyte with EC5–10 GABA for 90 seconds and then measuring the control peak evoked
current. After a 5-minute recovery period, the oocyte was perfused with MOC-
carboetomidate for 90 seconds and then with EC5–10 GABA plus MOC-carboetomidate for
90 seconds, and the peak evoked current was measured again. After a 15-minute recovery
period to allow MOC-carboetomidate washout, the control experiment (i.e., no MOC-
carboetomidate) was repeated to assure reversibility. The peak current response in the
presence of MOC-carboetomidate was then normalized to the average peak current response
of the two control experiments. MOC-carboetomidate-induced enhancement was quantified
from the normalized current responses in the presence versus absence of carboetomidate.
LORR in Rats
Rats were restrained in a 3-inch diameter, 9-inch long acrylic chamber. The desired dose of
MOC-carboetomidate or carboetomidate in dimethyl sulfoxide (DMSO) vehicle was
injected through the femoral venous catheter followed by a 1-ml normal saline flush. After
injection, rats were removed from the restraint device and turned supine. A rat was judged to
have LORR if it failed to right itself (onto all four paws) after drug administration. A
stopwatch was used to measure the duration of LORR, which was defined as the time from
hypnotic injection until the animal spontaneously righted itself. The ED50 for LORR was
determined from the dose dependence of LORR using the method of Waud. 17 In a separate
study, the induction time was measured in rats by administering MOC-carboetomidate or
carboetomidate (in DMSO vehicle) via the femoral venous catheter followed by a 1-ml
normal saline flush, immediately removing from the restraint device, and repeatedly turning
them supine until they no longer spontaneously righted. The induction time was defined as
the time from injection until LORR occurred.
In Vitro Metabolism in Pooled Rat Blood
Whole blood from 3 Sprague-Dawley rats (2.5 ml/rat) was drawn, immediately pooled,
anticoagulated with heparin (38 U), and aliquoted into 0.2 ml samples. Each pooled blood
sample was warmed at 37°C for 5 minutes and then sedative-hypnotic (20mM in DMSO)
was added to a final concentration of 100µM. After the desired incubation time, the
metabolic reaction was quenched with 0.2 ml acetonitrile (Sigma-Aldrich, St. Louis, MO).
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The samples were centrifuged and the resultant plasma separated and stored at −20°C until
analyzed. Sedative-hypnotic concentrations were determined in thawed plasma samples by
high-pressure liquid chromatography as described above for partition coefficient studies.
Rat Adrenocortical Suppression
Rats were restrained in a 3-inch diameter, 9-inch long acrylic chamber and given
dexamethasone (0.2 mg/kg; American Regent, Shirley, NY) IV to suppress endogenous
adrenocorticotropic hormone (ACTH) release and corticosterone production. Two hours
later, blood was drawn (to measure the baseline serum corticosterone concentration), and a
second dose of dexamethasone (0.2 mg/kg) was administered along with MOC-
carboetomidate, etomidate, or DMSO vehicle as a control. The concentrations of MOC-
carboetomidate and etomidate in DMSO were 38 and 2.9 mg/ml. Immediately after hypnotic
or vehicle administration, ACTH1–24 (25 µg/kg; Sigma-Aldrich Chemical Co, St. Louis,
MO) was given to stimulate corticosterone production followed by 1-ml normal saline flush.
Thirty minutes after ACTH1–24 administration, a second blood sample was drawn to
measure the ACTH1–24-stimulated serum corticosterone concentration. Rats in all three
groups (MOC-carboetomidate, etomidate, and vehicle control) received the same volume of
DMSO (0.7 ml/kg).
All blood draws were approximately 0.4 ml in volume. Corticosterone concentrations in
blood serum were determined as reported previously. Briefly, blood samples were allowed
to clot at room temperature (30–60 min) and then centrifuged at 3,500g for 5 min. Serum
was expressed from the resulting superficial fibrin clot and the sample was centrifuged again
at 3,500g for 5 min. After the second centrifugation step, the clot-free serum layer was
transferred to a fresh vial for final, high-speed centrifugation (16,000g, for 5min). The serum
was transferred to a clean vial and frozen (−20°C) pending corticosterone measurement.
After thawing and heat inactivation of corticosterone-binding globulins (65°C for 20 min),
serum baseline and ACTH1–24-stimulated corticosterone concentrations were quantified
using an enzyme-linked immunosorbent assay (Immunodiagnostic Systems Inc, Fountain
Hills, AZ) and a 96-well plate reader (Molecular Devices, Sunnyvale, CA).
Hemodynamic Effects
Rats were restrained in a 3-inch diameter, 9-inch long acrylic chamber and allowed to
acclimate for approximately 10–20 minutes before study. Arterial blood pressure was
recorded using a Propaq Encore 206EL monitor (Welsh Allyn Inc., Skaneateles Falls, NY)
every 30 s beginning 5 minutes before MOC-carboetomidate or DMSO vehicle
administration and then for 15 min thereafter. To keep the total volume of DMSO constant
at 0.7 ml/kg for all rats, the concentrations of MOC-carboetomidate in DMSO were 38 mg/
ml and 76 mg/ml when given at doses of 27 mg/kg and 54 mg/kg, respectively.
Statistical Analysis
All data are reported as mean ± SD unless otherwise noted. Statistical analysis and curve
fitting were performed using either Prism v5.0 for the Macintosh (GraphPad Software, Inc.,
LaJolla, CA) or Igor Pro 6.1 (Wavemetrics, Lake Oswego, OR). P < 0.05 indicates statistical
significance unless otherwise indicated. For multiple comparisons of biochemical and
physiological data derived from rats, we performed a one-way or two-way ANOVA
followed by a Tukey Multiple Comparison Test.
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MOC-carboetomidate is viscous oil at room temperature. Its octanol:water partition
coefficient was 3300 ± 280, whereas those for etomidate, carboetomidate, and MOC-
etomidate were 800 ± 180, 15000 ± 3700, and 190 ± 25, respectively.
As an initial screen of MOC-carboetomidate’s hypnotic activity, we assessed its ability to
produce LORR in tadpoles. We found that MOC-carboetomidate increased the fraction of
tadpoles that had LORR in a concentration-dependent manner and at the highest
concentration studied (40 µM), it produced LORR in all 10 tadpoles (Figure 3). This LORR
was reversible as 42 of 44 tadpoles that had LORR in our studies recovered their righting
reflexes when returned to fresh water. From the MOC-carboetomidate concentration-
dependence of LORR, we calculated an EC50 of 9 ± 1 µM.
MOC-carboetomidate also increased the fraction of rats that had LORR in a dose-dependent
manner and at the highest doses studied (20–200 mg/kg), it produced reversible LORR in all
rats. From the MOC-carboetomidate dose-response curve for LORR shown in Figure 4A,
we calculated MOC-carboetomidate’s ED50 to be 13 ± 5 mg/kg (n=27). For comparison, this
figure also shows the carboetomidate dose-response curve for LORR in rats, which yielded
an ED50 of 7.7 ± 0.8 mg/kg. Figure 4B plots the duration of LORR as a function of MOC-
carboetomidate or carboetomidate dose and demonstrates that for both sedative-hypnotics,
the duration of LORR increased with dose. However the slope of this relationship was
significantly shallower for MOC-carboetomidate than for carboetomidate (4 ± 1 vs. 15 ± 3,
respectively; p = 0. 0004123). We also determined the induction time upon administration of
the two hypnotics at doses equal to 4X their respective ED50s for LORR and found that they
were not significantly different at 16 ± 3 s (range: 10 – 18 s) for MOC-carboetomidate and
19 ± 6 s (range: 11 – 27 s) for carboetomidate.
To test whether enhanced GABAA receptor function might mediate this LORR, we assessed
MOC-carboetomidate’s ability to increase currents elicited by an EC5–10 GABA and
mediated a1b2g2L GABAA receptors. Figure 5 shows representative current traces obtained
from a single oocyte experiment and demonstrates that MOC-carboetomidate increased such
currents. At a MOC-carboetomidate concentration of 13 µM, the current magnitude
measured in 5 separate oocytes increased by 400 ± 100%.
MOC-carboetomidate was designed as a rapidly metabolized “soft” analog of
carboetomidate. We compared the metabolic stability of MOC-carboetomidate with those of
carboetomidate, MOC-etomidate, and etomidate by adding each sedative-hypnotic to pooled
rat blood and measuring the incubation time-dependent reduction in sedative-hypnotic
concentration. Figure 6 shows the percentage of unmetabolized drug remaining as a function
of incubation time in rat blood and reveals that neither carboetomidate nor etomidate was
significantly metabolized even after 20 minutes, our longest incubation time. In contrast,
MOC-carboetomidate and MOC-etomidate were metabolized in an approximately first-order
fashion with metabolic half-lives of 1.3 minutes (95% confidence intervals 1.0 – 1.6 min)
and 0.35 minutes (95% confidence intervals 0.22 – 0.84 min), respectively. In blood samples
containing MOC-carboetomidate and MOC-etomidate (but not carboetomidate or
etomidate), we also detected a higher polarity compound (as indicated by its shorter
chromatographic retention time) whose concentrations increased before reaching a plateau
of 0.82 minutes (95% confidence intervals 0.60 – 1.3 min) and 0.40 minutes (95%
confidence intervals 0.32 – 0.54 min), respectively (data not shown).
The effects of MOC-carboetomidate and etomidate on adrenocortical function were
compared by measuring the serum corticosterone concentrations in rats thirty minutes after
simultaneous administration of ACTH1–24 and either MOC-carboetomidate (27 mg/kg),
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etomidate (2mg/kg), or DMSO vehicle alone. These doses correspond to twice their
respective ED50s for producing LORR in rats. Baseline corticosterone concentrations before
ACTH1–24 administration were not significantly different among groups and averaged 26 ±
59 ng/ml. After ACTH1–24 administration, the average serum corticosterone concentration
of rats that received etomidate was 90 ± 44 ng/ml, which was significantly lower than that in
rats that received DMSO vehicle (460 ± 140 ng/ml; Figure 7). In contrast, the serum
corticosterone concentration of rats that received MOC-carboetomidate was 610 ± 280 ng/
ml. This was significantly higher than the serum corticosterone concentration in rats that
received etomidate and not significantly different from the concentration in rats that
received DMSO vehicle.
To determine whether the hemodynamic stability that is characteristic of etomidate, MOC-
etomidate, and carboetomidate is preserved in MOC-carboetomidate, we measured the effect
of MOC-carboetomidate at doses corresponding to 2× and 4× their ED50s for LORR in rats.
Figure 8 shows the change in mean arterial blood pressure after a single IV bolus of 27 mg/
kg MOC-etomidate, 54 mg/kg MOC-carboetomidate, or DMSO vehicle alone. Although
there was a decrease in mean arterial blood pressure in all three groups 30 seconds after
injection, the pressure recovered within one minute and was not significantly different at any
time point among groups during the entire experiment.
Discussion
The current study describes the synthesis and pharmacological activity of MOC-
carboetomidate, an etomidate analog that combines the two distinct structural features of
MOC-etomidate and carboetomidate into a single chemical entity. Its development was
motivated by the observation that MOC-etomidate and carboetomidate individually possess
pharmacological properties that could be desirable if present in a single drug. MOC-
etomidate is rapidly metabolized and produces hypnosis of extremely short duration because
it contains a metabolicallylabile ester moiety that renders it highly susceptible to ester
hydrolysis. 15 Carboetomidate is longer-acting, but does not suppress in vivo adrenocortical
function because the imidazole ring thought to be necessary for high affinity etomidate
binding to 11b-hydroxylase has been replaced with a pyrrole ring. 16 In the current studies,
we tested the hypothesis that MOC-etomidate’s metabolicallylabile ester group could be
added to carboetomidate to produce a new chemical entity that possessed features common
to both agents (i.e., GABAA receptor modulatory ability, potent hypnotic activity, and
hemodynamic stability) and the key desirable properties described above that each possesses
individually.
The current studies show that MOC-carboetomidate retains the GABAA receptor
modulatory ability and potent hypnotic activity that are characteristic of etomidate and the
two etomidate analogs upon which its structure is based. 15, 16, 18 With single bolus
injection, it also maintains hemodynamic stability similar to carboetomidate and better than
propofol, although we note that the DMSO vehicle that we used to formulate MOC-
carboetomidate (and carboetomidate in our previous studies) produced a brief reduction in
arterial blood pressure immediately after injection. However unlike etomidate and
carboetomidate (which were not detectably metabolized in rat blood even after 20 minutes),
MOC-carboetomidate was rapidly metabolized in blood. Its 1.3 min in vitro metabolic half-
life, while significantly slower than that of MOC-etomidate (0.35 min), was similar to that
reported for esmolol (2.27 min) 19, which also contains a metabolicallylabile ester moiety.
The modestly slower metabolism of MOC-carboetomidate as compared to MOC-etomidate
might be advantageous because it should reduce the quantity of drug required to maintain
anesthesia while retaining sufficiently rapid elimination to produce fast recovery.
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The slope of a plot of the duration of LORR versus the logarithm of the hypnotic dose
depends upon the rate of drug clearance from the brain and is independent of hypnotic
potency. 20, 21 We previously reported that this slope is shallower for MOC-etomidate than
for etomidate, which is consistent with faster MOC-etomidate brain clearance due to more
rapid metabolism. 15 This slope was also shallower for MOC-carboetomidate than for
carboetomidate; however, the difference (4-fold) was not as large as we had previously
measured when comparing MOC-etomidate versus etomidate (10-fold). In addition, the
duration of LORR was ~4-fold longer after administering MOC-carboetomidate than we had
previously observed upon administering equihypnotic doses of MOC-etomidate. 15 These
results suggest that while MOC-carboetomidate is cleared from the brain more rapidly than
carboetomidate, it is not cleared as quickly as MOC-etomidate perhaps because it is
metabolized more slowly.
We administered MOC-carboetomidate dissolved in the organic solvent DMSO. This is a
common approach with hydrophobic drugs during preclinical development because defining
an optimal IV formulation can be time-consuming and expensive. However, it should be
noted that formulation may affect the actions of very hydrophobic drugs. For example, Dutta
and Ebling found that LORR occurred significantly more slowly and
electroencephalographic burst suppression required higher doses when propofol was
dissolved in an organic solvent (ethanol) rather than formulated as an emulsion. 22 This
group subsequently measured 300-fold higher peak lung propofol concentrations in rats that
received brief infusions of nonemulsified versus emulsified propofol and concluded that
pulmonary uptake and release significantly slows the increase and decrease of arterial and
brain concentrations of nonemulsified propofol and reduces peak brain concentrations. 23 If
MOC-carboetomidate (or carboetomidate) administered in DMSO is similarly sequestered
by the lung, then optimal formulation may reduce induction time and increase hypnotic
potency. Alternately, it might be possible to develop less hydrophobic analogues of MOC-
carboetomidate (or carboetomidate) that do not require formulation in an emulsion and have
more rapid onset of action.
In conclusion, MOC-carboetomidate combines the unique structural features of MOC-
etomidate and carboetomidate into a single chemical entity. It is a GABAA receptor
modulator with potent hypnotic activity that is more rapidly metabolized and cleared from
the brain than carboetomidate, maintains hemodynamic stability, and does not suppress
adrenocortical function.
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Chemical structures of etomidate, MOC-etomidate, carboetomidate, and MOC-
carboetomidate. Their structural differences are highlighted by the dashed boxes.
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MOC-carboetomidate concentration-response curve for loss of righting reflexes (LORR) in
tadpoles. Each point represents data from a single tadpole. The curve is a fit of the
concentration-response data to a logistic equation using the method of Waud. 17 The
calculated EC50 for LORR was 9 ± 1 µM.
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Loss of righting reflexes (LORR) in rats. (A) MOC-carboetomidate and carboetomidate
dose-responses curves for LORR in rats. The curve is a fit of dose-response data to a logistic
equation using the method of Waud. 17 The calculated ED50s for LORR were 13 ± 4 mg/kg
for MOC-carboetomidate and 7.7 ± 0.8 mg/kg for carboetomidate. (B) Time to righting after
bolus administration of MOC-carboetomidate or carboetomidate at the indicated doses. For
both drugs, the time to righting increased logarithmically with dose. However, the slope of
this relationship was significantly shallower for MOC-carboetomidate than for
carboetomidate (4 ± 1 vs. 15 ± 3, respectively; p = 0. 0004123).
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Representative traces showing the enhancing effect of MOC-carboetomidate on human γ-
aminobutyric acid type A receptor function. The first and last traces show the control
electrophysiological responses elicited with 3 µM γ-aminobutyric acid alone. The middle
trace demonstrates the enhancing effect of 13 µM MOC-carboetomidate on currents elicited
with 3 µM γ-aminobutyric acid in the same oocyte.
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Metabolic stability of sedative-hypnotics in rat blood. Each point is the average value
determined in two separate experiments. Each experiment used blood pooled from a
different group of three rats. The metabolic half-lives of MOC-carboetomidate and MOC-
etomidate were 1.3 min and 0.35 min, respectively.
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The differential effects of MOC-carboetomidate (27 mg/kg) and etomidate (2 mg/kg) on
adrenocortical function in the rat. These doses correspond to twice the respective ED50s for
loss of righting reflexes. Adrenocorticotropic hormone1–24 was given simultaneously with
sedative-hypnotic to stimulate corticosterone production and serum corticosterone
concentrations were measured 30 minutes later. Four rats were studied in each group.
Average corticosterone concentrations (±SD) were 460 ± 140 ng/ml in the vehicle control
group, 90 ± 44 ng/ml in the etomidate group, and 610 ± 280 ng/ml in the MOC-
carboetomidate group. *, P < 0.05; **, P < 0.01; NS, no significant difference.
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The effects of MOC-carboetomidate on mean arterial blood pressure in the rat. MOC-
carboetomidate (27 mg/kg or 54 mg/kg) in dimethyl sulfoxide vehicle or vehicle alone was
administered IV at time 0. In all three groups, there was a significant decrease in mean
arterial blood pressure 30 s after injection. However among the three groups, the mean blood
pressure was not significantly different at any time point during the experiment.
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